Nicolas Werbeck

This inventor holds 18 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Macrocyclic Compounds. Top assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc.. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicolas Werbeck. Retrieved from https://idiyas.com/inventor/nicolas-werbeck

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 6)

% Patents Active = 94.4

CIPO Patents = 1 (Patent Applications = 11)

EPO Patents = 8 (Patent Applications = 17)

Average Co-Inventor Count = 14.1

ph-index = 3

Forward Citations = 35(Granted Patents)

Location History:

Berlin, DE (2019 - 2023)
Leverkusen, DE (2022 - 2024)
Freiburg, DE (2024)

Company Filing History:

14 out of 12,268

Bayer Aktiengesellschaft

patents

14 out of 387

Bayer Pharma Aktiengesellschaft

patents

8 out of 488

The Broad Institute, Inc.

patents

4. 3 out of 159

Deutsches Krebsforschungszentrum

patents

5. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2019-2026

Loading Chart...

Areas of Expertise:

DGK Inhibitors

Macrocyclic Compounds

Indole Derivatives

Aminothiazoles

Aminoquinolones

Fluorine Substituted

Chlorine Substituted

Sulfondiimine Compounds

PTEFb Inhibition

Substituted Derivatives

Immune Activation

Modified Compounds

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12673927 - SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION (2026-07-07),

2. 12478621 - SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION (2025-11-25),

3. 12152041 - Macrocyclic fluorine substituted indole derivatives (2024-11-26),

4. 11998539 - Substituted aminoquinolones as DGKalpha inhibitors for immune activation (2024-06-04),

5. 11964953 - Substituted aminothiazoles as DGKzeta inhibitors for immune activation (2024-04-23),

6. 11891404 - Substituted macrocyclic indole derivatives (2024-02-06),

7. 11691986 - PTEFB inhibiting macrocyclic compounds (2023-07-04),

8. 11492358 - Macrocyclic indole derivatives (2022-11-08),

9. 11478451 - Macrocyclic chlorine substituted indole derivatives (2022-10-25),

10. 11447504 - Macrocyclic chlorine substituted indole derivatives (2022-09-20),

11. 11440923 - Substituted macrocyclic indole derivatives (2022-09-13),

12. 11401278 - Macrocyclic indole derivatives (2022-08-02),

13. 11286263 - Macrocyclic fluorine substituted indole derivatives (2022-03-29),

14. 11254690 - PTEFb inhibiting macrocyclic compounds (2022-02-22),

15. 11242356 - PTEFb inhibiting macrocyclic compounds (2022-02-08),

Title: The Innovative Journey of Inventor Nicolas Werbeck

Introduction: Nicolas Werbeck is a visionary inventor based in Leverkusen, Germany, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Nicolas Werbeck holds several patents in the areas of renewable energy, sustainable materials, and advanced robotics, showcasing his commitment to creating a more efficient and eco-friendly future.

Career Highlights: With a background in engineering and a passion for pushing the boundaries of what is possible, Werbeck has led numerous successful projects that have revolutionized industries and improved the quality of life for many.

Collaborations: Throughout his career, Nicolas Werbeck has collaborated with leading research institutions, universities, and innovative companies to bring his ideas to life and make a lasting impact on the world.

Conclusion: Nicolas Werbeck's dedication to innovation and his relentless pursuit of excellence have solidified his reputation as a pioneering inventor in Leverkusen, Germany, and beyond. His work continues to inspire future generations of inventors to think boldly and create solutions that shape a better tomorrow.

Profile summary based on public USPTO records.